Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 60


Community awareness, use and preference for pandemic influenza vaccines in Pune, India.

Sundaram N, Purohit V, Schaetti C, Kudale A, Joseph S, Weiss MG.

Hum Vaccin Immunother. 2015 Oct 3;11(10):2376-88. doi: 10.1080/21645515.2015.1062956.


Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.

Ramezanpour B, Pronker ES, Kreijtz JH, Osterhaus AD, Claassen E.

Vaccine. 2015 Aug 20;33(35):4349-58. doi: 10.1016/j.vaccine.2015.04.086. Epub 2015 Jun 3.


Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC.

Liang Z, Mao Q, Wang Y, Li C, Gao K, Wang J.

Emerg Microbes Infect. 2014 Sep;3(9):e67. doi: 10.1038/emi.2014.66. Epub 2014 Sep 17. Review.


Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.

Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS.

PLoS Med. 2015 Mar 24;12(3):e1001807. doi: 10.1371/journal.pmed.1001807. eCollection 2015 Mar.


Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.


Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants: randomized, observer-masked, single-center clinical study.

Wang S, Dong J, Chai W, Li F, Wang S, Sun B, Chen Z.

Springerplus. 2014 Jul 31;3:397. doi: 10.1186/2193-1801-3-397. eCollection 2014.


Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women.

Ma F, Zhang L, Jiang R, Zhang J, Wang H, Gao X, Li X, Liu Y.

Clin Vaccine Immunol. 2014 Sep;21(9):1282-7. doi: 10.1128/CVI.00375-14. Epub 2014 Jul 2.


The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.

Yokomichi H, Kurihara S, Yokoyama T, Inoue E, Tanaka-Taya K, Kono S, Yamagata Z.

PLoS One. 2014 Feb 25;9(2):e88927. doi: 10.1371/journal.pone.0088927. eCollection 2014.


Optimized strategy for the control and prevention of newly emerging influenza revealed by the spread dynamics model.

Zhang WD, Zu ZH, Xu Q, Xu ZJ, Liu JJ, Zheng T.

PLoS One. 2014 Jan 2;9(1):e84694. doi: 10.1371/journal.pone.0084694. eCollection 2014. Erratum in: PLoS One. 2014;9(1). doi: 10.1371/annotation/8254081b-b193-4799-9ddf-d9a71d2007b4.


The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study.

Yang Z, Wang S, Li W, Li C, Dong J, Li F, Wang S, Chai W, Sun B, Chen Z.

Results Immunol. 2012 Oct 9;2:184-9. doi: 10.1016/j.rinim.2012.10.001. eCollection 2012.


AHRQ prevention quality indicators to assess the quality of primary care of local providers: a pilot study from Italy.

Manzoli L, Flacco ME, De Vito C, Arcà S, Carle F, Capasso L, Marzuillo C, Muraglia A, Samani F, Villari P.

Eur J Public Health. 2014 Oct;24(5):745-50. doi: 10.1093/eurpub/ckt203. Epub 2013 Dec 23.


Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.

Onlamoon N, Unpol P, Boonchan M, Sukapirom K, Wittawatmongkol O, Chokephaibulkit K, Ammaranond P, Pattanapanyasat K.

Dis Markers. 2013;35(4):221-7. doi: 10.1155/2013/276547. Epub 2013 Sep 5.


The expected number of background disease events during mass immunization in China.

Wang Y, Wu L, Yu X, Zhao F, Russell A, Song M, Wang W.

PLoS One. 2013 Aug 20;8(8):e71818. doi: 10.1371/journal.pone.0071818. eCollection 2013.


Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes.

Wang H, Ma C, Lu Y, Ji X, Pang Y, Hua F, Cui L, Ba D, He W.

Cell Mol Immunol. 2013 Sep;10(5):403-12. doi: 10.1038/cmi.2013.25. Epub 2013 Aug 5.


Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.

Luo FJ, Yang LQ, Ai X, Bai YH, Wu J, Li SM, Zhang Z, Lu M, Li L, Wang ZY, Shi NM.

Hum Vaccin Immunother. 2013 Aug;9(8):1725-34. doi: 10.4161/hv.24832. Epub 2013 Jun 4.


A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region.

Samaan G, McPherson M, Partridge J.

PLoS One. 2013 Jul 16;8(7):e70003. doi: 10.1371/journal.pone.0070003. Print 2013. Review.


Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.

BMC Infect Dis. 2013 May 20;13:224. doi: 10.1186/1471-2334-13-224.


Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.

Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, Wang Y, Zhao P, Qi Z.

PLoS One. 2013;8(3):e58810. doi: 10.1371/journal.pone.0058810. Epub 2013 Mar 19.


Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy.

Miossi R, Fuller R, Moraes JC, Ribeiro AC, Saad CG, Aikawa NE, Miraglia JL, Ishida MA, Bonfa E, Caleiro MT.

Clinics (Sao Paulo). 2013;68(2):129-34.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk